Want to see AU:TRI full AI Analyst Report?
Top Page
TrivarX Limited
(Sydney:TRI)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
▼(-45.00% Downside)
Action:Reiterated
Date:09/25/26
The score is driven primarily by weak financial performance—zero reported revenue, sharply widening losses in 2026, and continued operating cash burn—despite low balance-sheet leverage. Technicals add a bearish tilt with the price below major moving averages and negative MACD (only partially offset by near-oversold RSI/Stoch). Valuation provides little support due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Low Leverage
Minimal debt relative to equity reduces near-term solvency pressure and limits mandatory interest or repayment demands. This gives TrivarX greater balance-sheet flexibility while it addresses operating weaknesses, although low leverage alone does not establish a path to profitability.
Negative Factors
No Reported Revenue
Three consecutive years of zero reported revenue provide no demonstrated revenue engine in the financial statements and leave the cost base uncovered. Without visible sales generation, durable operating scale and future self-funded growth remain unestablished over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt relative to equity reduces near-term solvency pressure and limits mandatory interest or repayment demands. This gives TrivarX greater balance-sheet flexibility while it addresses operating weaknesses, although low leverage alone does not establish a path to profitability.
Read all positive factors
TrivarX Limited (TRI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$12.69M
Dividend YieldN/A
Average Volume (3M)788.41K
Price to Earnings (P/E)―
Beta (1Y)2.32
Revenue GrowthN/A
EPS Growth-336.84%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.95
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,250,508
30 Day Avg. Volume788,406
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.01
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TrivarX Limited Business Overview & Revenue Model
Company Description
Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market pre...
TrivarX Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | -6.47M | -52.47K | -93.13K |
| EBITDA | -1.95M | -1.89M | -1.13M |
| Net Income | -8.76M | -943.23K | -1.24M |
Balance Sheet | |||
| Total Assets | 16.53M | 13.48M | 10.81M |
| Cash, Cash Equivalents and Short-Term Investments | 2.44M | 1.25M | 848.10K |
| Total Debt | 128.14K | 169.03K | 15.90K |
| Total Liabilities | 565.64K | 831.22K | 1.18M |
| Stockholders Equity | 15.97M | 12.65M | 9.88M |
Cash Flow | |||
| Free Cash Flow | 0.00 | -189.74K | -3.70M |
| Operating Cash Flow | -1.51M | -189.74K | -1.48M |
| Investing Cash Flow | -1.17M | -2.09M | -2.85M |
| Financing Cash Flow | 3.87M | 2.68M | 4.32M |
TrivarX Limited Technical Analysis
Negative
0.02
Price Trends
0.01
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
32.93
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.93 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRI.
TrivarX Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$34.35M | 22.50 | 13.72% | ― | 42.25% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$15.02M | ― | -578.72% | ― | 113.42% | 29.17% | |
47 Neutral | AU$20.06M | -2.21 | -1688.04% | ― | 11.45% | 0.69% | |
43 Neutral | AU$35.14M | -3.13 | -18.10% | ― | ― | ― | |
41 Neutral | AU$12.69M | -0.01 | -44.34% | ― | ― | -336.84% | |
41 Neutral | AU$7.66M | -0.38 | -614.15% | ― | -46.09% | 70.70% |
* Healthcare Sector Average
AU:TRI
TrivarX Limited
0.01
<0.01
10.00%
AU:RHT
Resonance Health Ltd
0.07
0.04
100.00%
AU:PKY
Opyl Ltd.
0.03
<0.01
13.04%
AU:AHE
MedAdvisor Limited
0.01
-0.03
-71.43%
AU:ICR
InteliCare Holdings Limited
0.02
>-0.01
-25.00%
AU:PCK
PainChek Ltd
0.10
-0.47
-83.16%
TrivarX Limited Corporate Events
TrivarX advances Stabl-Im platform toward clinical feasibility study
Sep 23, 2026
TrivarX has reported steady progress in the clinical and technical development of its Stabl-Im platform, with pre-clinical study designs completed and animal studies underway to support a planned clinical feasibility trial. The company has also fi...
TrivarX Sets AGM Date and Director Nomination Deadline
Sep 21, 2026
TrivarX Limited has scheduled its Annual General Meeting for 19 November 2026, with further details to be provided to shareholders in forthcoming AGM materials. The company has also set 30 September 2026 as the deadline for written director nomina...
TrivarX posts steep annual loss as revenue collapses but per-share asset backing rises
Aug 27, 2026
TrivarX Limited has reported a sharp deterioration in its financial performance for the year ended 30 June 2026, with revenue from ordinary activities plunging to $14,566 from $1.13 million a year earlier. The company’s net loss attributable...
TrivarX refocuses on Stabl-Im as new CEO drives clinical push
Jul 28, 2026
TrivarX has sharpened its development strategy under new chief executive Dr Danielle Meyrick, prioritising disciplined clinical execution and capital allocation around its Stabl-Im imaging platform while limiting near-term spend on mental health t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.